Tumor microenvironment targeted therapies to address the key challenges of non-responsiveness and resistance to existing cancer treatments.

Areas of Interest and Expertise:

Therapeutic resistance poses a significant challenge in the treatment of cancer. To overcome this obstacle, researchers and clinicians have increasingly shifted their attention to the intricate interplay between tumors and their microenvironment. By understanding the complex interactions within the tumor microenvironment, novel strategies can be developed to combat therapeutic resistance and enhance treatment outcomes.

Building on its world-leading expertise in signal transduction research, protein engineering, medicinal chemistry, and structure-based drug design, SLC strives to develop small-molecule inhibitors of signaling proteins implicated in the interplay between tumor cells and the tumor microenvironment with the goal to overcome refractoriness/resistance to cancer therapies.

Publications and Presentations